GlassScriptPhysician profile
Nikolas Dimovski
NPI 1003109216
$2,705.74
in general payments reported to CMS, 2019-2025
28 companies · $992 in 2025
The $992 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $144 · 2021: $118 · 2022: $98.63 · 2023: $204 · 2024: $1,015 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $739.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $235.45 | 2019-2025 | |
| Abbvie INC. | $222.80 | 2023-2025 | Viberzi, Linzess |
| Lilly USA, LLC | $190.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $179.38 | 2019-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.16 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.16 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $88.45 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $88.41 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $76.95 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.10 | 2024-2025 | Jardiance |
| Lnhc, INC | $59.28 | 2025 | Zelsuvmi |
| Dexcom, INC. | $59.06 | 2024 | Dexcom G6 Transmitter |
| Ars Pharmaceuticals Operations, INC. | $49.78 | 2025 | Neffy |
| Exact Sciences Corporation | $48.03 | 2024-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $46.08 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $45.64 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $39.85 | 2023-2024 | Voquezna |
| Allergan, INC. | $30.35 | 2019-2020 | |
| Optinose US, INC. | $29.35 | 2024 | |
| Medtronic, INC. | $28.17 | 2024 | Interstim |
| Janssen Pharmaceuticals, INC | $22.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.40 | 2024 | |
| Abbott Laboratories | $17.64 | 2024 | Freestyle Libre 3 |
| Alk-Abello, INC | $17.43 | 2024 | Odactra, Ragwitek, Grastek |
| Esperion Therapeutics, INC. | $16.10 | 2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $14.00 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikolas Dimovski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.